Vyndaqel Capsules Special Investigation (ATTR-CM)
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,214actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-03 | actual | When the study began enrolling |
| Primary completion | 2025-03-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-27 | actual | The whole study's end, after follow-up |
| First posted | 2019-09-27 | actual | When this record first appeared on the registry |
| Results posted | 2026-05-18 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
- Drug: Treatment for TTR amyloidosis — also filed as Vyndaqel
- Drug: Treatment for TTR amyloidosis — also filed as Vynmac
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Adverse Drug Reactions
measured 30 months,Participants who discontinued this drug during the observation period, the observation period was until the first visit after the date of discontinuation.
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-10-24 · 4.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-01-23 · 2.1 MB · SAP_001.pdf
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed